Kyrgyzstan vs Russia: The number of people with susceptibility test result for rifampicin
Kyrgyzstan
94.01
in 2021
Russia
93.52
in 2021
Kyrgyzstan rank
56th
Russia rank
57th
The number of people with susceptibility test result for rifampicin over time
- Kyrgyzstan
- Russia
How they compare
Kyrgyzstan currently reports 94.01 against 93.52 in Russia, a difference of 0.49.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Russia ahead.
Kyrgyzstan ranks 56th and Russia ranks 57th of 146 countries.
Kyrgyzstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Russia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 89.91 | 88.47 | 1.44 | Kyrgyzstan |
| 2020s | 93.02 | 93.01 | 0.009 | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Kyrgyzstan or Russia?
- Kyrgyzstan, at 94.01 against 93.52 in Russia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Kyrgyzstan and Russia?
- 0.49, with Kyrgyzstan ahead.
- How many years of comparable data are there for Kyrgyzstan and Russia?
- 5 years are reported by both, from 2017 to 2021.
- How do Kyrgyzstan and Russia rank globally for the number of people with susceptibility test result for rifampicin?
- Kyrgyzstan ranks 56th and Russia ranks 57th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.